Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. Belgium /
    2. Our innovation /
    3. Focus areas /
    4. Oncology

    Oncology

    We are a team of innovators driven by our vision to eliminate cancer. We work diligently to get in front of cancer, and we will never settle until the disease is behind everyone. With more than 30 years of delivering transformational innovations in oncology, our commitment to pioneer new frontiers and therapies for patients has never been stronger as we strive to redefine treatment paradigms in hematologic malignances and solid tumors.

    Despite the incredible work of the oncology community across Europe, cancer remains the second leading cause of premature death in this region.[1][2] We fiercely believe cancer is a challenge we can collectively overcome, and our ultimate aim is to make cancer an interceptable, even curable, or chronic disease.

    We know that receiving a cancer diagnosis can be overwhelming and sparks fear. We are striving to change this, so that one day the words “you have cancer” will be less terrifying for patients to hear and less distressing for healthcare professionals to say and act upon.
    jjmtim-photo-patientcomfort-01-9256.jpg

    Our precise purpose

    Every cancer is different, each possessing unique challenges along the way.[3] We are precisely focused on mastering the areas where we can make the most meaningful difference for patients, partners, and the entire oncology community. To do this, we consistently integrate patients’ perspectives into everything we do.

    Our pipeline is taking science from where it is to where it has not been before, through targeted transformation. Our areas of focus include:

    • 11-20224-multiple-myeloma.webp

      Multiple myeloma

      We want to improve treatment efficacy for patients with this rare, incurable blood cancer.
    • 11-2024b-cell-malignancies.webp

      B-cell malignancies

      There are many different types of B cell malignancies.[1] We’re focused on three main types, CLL (chronic lymphocytic leukemia), MCL (mantle cell lymphoma) and WM (Waldenstrom macroglobulinemia).
    • 11-2024-prostate-cancer.webp

      Prostate cancer

      We have over ten years’ experience in research in prostate cancer, the most common cancer among men in the EU.[1]
    • 11-2024-bladder-cancer.webp

      Bladder cancer

      Despite therapies being available, there is a high unmet need in bladder cancer due to poor outcomes.[1] We are striving to change that.
    • 11-2024-lung-cancer.webp

      Lung cancer

      We’re concentrating on developing targeted therapies for patients with lung cancer, the leading cause of cancer death for men and women globally.

    [1] World Health Organization Regional Office for Europe. Cancer data and statistics. Available at https://www.who.int/health-topics/noncommunicable-diseases#tab=tab_1 Accessed December 2020.
    [2] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-387.
    [3] Ogino S. et al. Expert Rev Mol Diagn. 2012; 12(6): 621–628. 2 TBC

    © Janssen-Cilag NV/B.V., a Johnson&Johnson company – CP-490848 – Approval date: 11-2024, vu/er Luc Van Oevelen, Antwerpseweg 15-17, 2340 Beerse